Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Ezogabine (retigabine)

Nature Reviews Drug Discovery volume 10, pages 729–730 (2011)Cite this article

Subjects

Abstract

Ezogabine (Potiga; Valeant Pharmaceuticals/GlaxoSmithKline), a potassium channel opener, was approved in June 2011 by the US Food and Drug Administration (FDA) for the adjunctive treatment of partial-onset seizures in adult patients. The same drug was granted marketing authorization for this indication in the European Union in March 2011, where it is known as retigabine (Trobalt).

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Structure of ezogabine.

References

  1. Bialer, M. & White, H. S. Key factors in the discovery and development of new antiepileptic drugs. Nature Rev. Drug Discov. 9, 68–82 (2010).

    Article  CAS  Google Scholar 

  2. Rostock A. et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res. 23, 211–223 (1996).

    Article  CAS  Google Scholar 

  3. Rundfeldt, C. The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells. Eur. J. Pharmacol. 336, 243–249 (1997).

    Article  CAS  Google Scholar 

  4. US Food and Drug Administration. FDA labeling information — Potiga. FDA website [online], (2011).

  5. European Medicines Agency (EMA). European Public Assessment Report — Trobalt. EMA website [online], (2011).

  6. Porter, R. J. et al. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 68, 1197–2004 (2007).

    Article  CAS  Google Scholar 

  7. French, J. A. et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 76, 1555–1563 (2011).

    Article  CAS  Google Scholar 

  8. Brodie, M. J. et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 75, 1817–1824 (2010).

    Article  CAS  Google Scholar 

  9. Schmidt, D. Efficacy of new antiepileptic drugs. Epilepsy Curr. 11, 9–11 (2011).

    Article  Google Scholar 

  10. Faught, E. Ezogabine: a new angle on potassium gates. Epilepsy Curr. 11, 75–78 (2011).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Carl E. Stafstrom is at the University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53705, USA.,

    Carl E. Stafstrom

  2. Seden Grippon is at IMS Health, 7 Harewood Avenue, London NW1 6JB, UK.,

    Seden Grippon

  3. Peter Kirkpatrick is at Nature Reviews Drug Discovery.,

    Peter Kirkpatrick

Authors
  1. Carl E. Stafstrom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seden Grippon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Carl E. Stafstrom, Seden Grippon or Peter Kirkpatrick.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stafstrom, C., Grippon, S. & Kirkpatrick, P. Ezogabine (retigabine). Nat Rev Drug Discov 10, 729–730 (2011). https://doi.org/10.1038/nrd3561

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3561

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research